Immunoglobulin G (IgG): Understanding Your Blood Test Series

1. Overview: What this test reveals and why it is important

Immunoglobulin G (IgG) is the most abundant antibody class in human blood, constituting approximately 75–80% of circulating immunoglobulins. It is the cornerstone of long‑term humoral immunity. IgG is produced by plasma cells in response to prior infection or vaccination, providing durable protection against bacteria, viruses, and toxins. It crosses the placenta, conferring passive immunity to the newborn. Total IgG measurement assesses overall humoral immune status. Low IgG suggests immunodeficiency; high IgG indicates chronic infection, inflammation, or autoimmune disease. Unlike IgE, IgG is not primarily allergic—it is the memory antibody. Specific IgG assays can also document past exposure to certain pathogens (e.g., varicella, CMV, EBV) or vaccine response. Four subclasses (IgG1–4) exist; subclass deficiencies may occur despite normal total IgG.

---

2. What does it measure

a. Units of measurement

· Grams per litre (g/L) – most common worldwide

· Milligrams per decilitre (mg/dL) – used in some countries; conversion: g/L × 100 = mg/dL

b. Normal Range (adult reference intervals vary by laboratory; age‑dependent)

· Adults: 7.0 – 16.0 g/L (700 – 1600 mg/dL)

· Children:

· Birth – 1 month: 6.0 – 12.0 g/L (maternal IgG)

· 1 – 6 months: 3.0 – 8.0 g/L (physiological nadir)

· 6 months – 2 years: 4.0 – 10.0 g/L

· 2 – 6 years: 5.0 – 12.0 g/L

· 6 – 12 years: 6.0 – 14.0 g/L

· 12 – 16 years: 7.0 – 15.0 g/L

Note: IgG subclass reference ranges differ; consult specific laboratory values.

---

3. Other factors connected to this

a. Direct correlation (factors that directly raise total IgG)

· Chronic infection – tuberculosis, osteomyelitis, bronchiectasis, chronic viral hepatitis (HBV, HCV), HIV, EBV, CMV.

· Autoimmune diseases – systemic lupus erythematosus (SLE), rheumatoid arthritis, Sjögren's syndrome, IgG4‑related disease.

· Liver disease – chronic active hepatitis, cirrhosis (polyclonal gammopathy).

· Sarcoidosis – polyclonal hypergammaglobulinaemia common.

· HIV/AIDS – polyclonal B‑cell activation; paradoxically, late disease may show hypogammaglobulinaemia.

· Multiple myeloma – IgG monoclonal gammopathy (very high levels, often >30 g/L).

· Monoclonal gammopathy of undetermined significance (MGUS) – elevated IgG with monoclonal spike but no end‑organ damage.

· Castleman disease – lymphoproliferative disorder with marked hypergammaglobulinaemia.

· Immunisations – transient rise following vaccination.

b. Indirect correlation (factors that influence IgG independently or falsely)

· Age –

· Infants: low endogenous IgG until ~6 months; physiological nadir at 3–6 months.

· Elderly: may show modest decline or increase with chronic disease.

· Pregnancy – slight physiological decline due to haemodilution; placental transfer to fetus.

· Medications –

· Lower IgG: corticosteroids, immunosuppressants (azathioprine, mycophenolate), anticonvulsants (phenytoin, carbamazepine), rituximab (B‑cell depletion).

· Raise IgG: interferons, IVIG therapy (exogenous).

· Protein‑losing states – enteropathy, nephrotic syndrome, severe burns → low IgG (not high).

· Haemodilution / overhydration – spuriously low values.

· Assay interference – very high rheumatoid factor, heterophile antibodies; monoclonal proteins can interfere with nephelometry.

c. IgG subclasses – key distinctions

· IgG1 – 60–70% of total IgG; responds to protein antigens (viruses, vaccines).

· IgG2 – 20–30%; responds to polysaccharide antigens (encapsulated bacteria: pneumococcus, meningococcus, Haemophilus).

· IgG3 – 5–8%; potent pro‑inflammatory, short half‑life; responses to viral infections.

· IgG4 – 2–4%; unique functional monovalency; elevated in IgG4‑related disease (autoimmune pancreatitis, retroperitoneal fibrosis) and chronic antigen exposure (allergen immunotherapy, beekeeping).

Clinical pearl: Selective IgG2 or IgG3 deficiency can occur with normal total IgG and manifest as recurrent sinopulmonary infections.

---

4. Disorders related to abnormal values

a. When elevated (hypergammaglobulinaemia)

Polyclonal (broad increase, many immunoglobulins)

· Chronic infections

· Autoimmune connective tissue diseases (SLE, RA, Sjögren's)

· Liver disease (chronic hepatitis, cirrhosis)

· Sarcoidosis

· HIV (early stage)

Monoclonal (single clone, spike on electrophoresis)

· Multiple myeloma – IgG myeloma most common; associated with anaemia, renal impairment, lytic bone lesions, immunosuppression.

· MGUS – asymptomatic; risk of progression to myeloma ~1% per year.

· Waldenström macroglobulinaemia – IgM, not IgG; distinction important.

· Primary amyloidosis – may have associated monoclonal IgG.

· POEMS syndrome – polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes.

IgG4‑related disease

· Elevated IgG4 (often >1.35 g/L); tissue infiltration with IgG4‑positive plasma cells; responds dramatically to corticosteroids.

b. When low (hypogammaglobulinaemia)

Primary immunodeficiencies

· Common variable immunodeficiency (CVID) – most common symptomatic primary immunodeficiency; low IgG ± low IgA/IgM; recurrent infections, autoimmune complications, enteropathy.

· X‑linked agammaglobulinaemia (Bruton) – boys; near‑absent B cells and all immunoglobulins; presents in infancy.

· Selective IgG subclass deficiency – normal total IgG but deficient in one or more subclasses; recurrent sinopulmonary infections.

· Specific antibody deficiency – normal IgG and subclasses but impaired response to polysaccharide vaccines.

· Transient hypogammaglobulinaemia of infancy – prolonged physiological nadir; resolves spontaneously by age 2–4 years.

Secondary immunodeficiencies

· Chronic lymphocytic leukaemia (CLL) – progressive hypogammaglobulinaemia with advanced disease.

· Multiple myeloma – non‑myeloma immunoglobulins are suppressed (immunoparesis).

· Nephrotic syndrome – urinary IgG loss.

· Protein‑losing enteropathy – intestinal loss of immunoglobulins.

· Severe burns – cutaneous loss.

· Immunosuppressive drugs – corticosteroids, rituximab, mycophenolate.

· Malnutrition / zinc deficiency – impaired antibody synthesis.

Normal variant

· Approximately 0.1% of healthy adults have incidental IgG slightly below reference range without infection susceptibility; requires confirmation and subclass assessment.

---

5. Best way to address aberrant levels

Important principle: IgG is a marker of immune status, not a target for direct manipulation. Treat the underlying condition—infection, autoimmunity, B‑cell malignancy, or immunoglobulin deficiency—not the IgG number. Raising IgG in a patient with primary immunodeficiency requires immunoglobulin replacement therapy, not dietary supplements. Lowering IgG in monoclonal gammopathy requires chemotherapy directed at the plasma cell clone. Self‑directed attempts to alter IgG are ineffective and potentially dangerous.

a. Quick ways or using Medications

For LOW IgG (hypogammaglobulinaemia)

· Immunoglobulin replacement therapy –

· IVIG (intravenous immunoglobulin) or SCIG (subcutaneous immunoglobulin) .

· Pooled human IgG from thousands of donors; administered every 3–4 weeks (IV) or weekly (SC).

· Indications: Primary immunodeficiency (CVID, XLA), secondary immunodeficiency with recurrent infections, certain autoimmune conditions (Kawasaki, Guillain–Barré, ITP).

· Do not self‑administer; requires specialist supervision, infusion centre or home care training.

· Ecological note: IVIG is a human‑derived blood product, not replaceable by plant or biotech alternatives. Conservation is essential; wastage is unacceptable.

· Treat underlying cause –

· Discontinue offending drug (phenytoin, carbamazepine, rituximab – if safe).

· Treat protein‑losing states – manage nephrotic syndrome, enteropathy.

· Supportive care – prompt antibiotics for infections; vaccination when appropriate.

For HIGH IgG (hypergammaglobulinaemia)

· Monoclonal (myeloma, MGUS) –

· Myeloma: chemotherapy (proteasome inhibitors, immunomodulators, steroids, autologous stem cell transplant); directed at plasma cell clone. IgG declines slowly over months.

· MGUS: no treatment unless high‑risk progression; surveillance only.

· Polyclonal (autoimmune, chronic infection) –

· Treat underlying disease – DMARDs for SLE/RA, antivirals/antibiotics for chronic infection, corticosteroids for sarcoidosis.

· IgG4‑related disease – corticosteroids (dramatic response); rituximab for refractory cases.

· Do not self‑prescribe immunosuppressants or chemotherapy.

b. Using Supplements or Holistic medicine

Important: No supplement can replace IgG in immunodeficiency. Supplements play a supportive role in maintaining overall immune competence but do not correct IgG deficiency. Their use is adjunctive and should never delay definitive diagnosis or immunoglobulin therapy.

· Vitamin D – deficiency impairs antibody responses; supplementation improves vaccine responses.

· Preferred: D3 (cholecalciferol from lichen). Target serum 25‑OH‑D >30 ng/mL.

· Zinc – essential for B‑cell development and antibody production. Deficiency causes acquired hypogammaglobulinaemia.

· Preferred forms: zinc picolinate, zinc citrate.

· Dose: 15–30 mg elemental zinc daily; avoid chronic high doses (copper depletion).

· Vitamin C – supports immune cell function; deficiency impairs humoral immunity.

· Whole food sources: amla (Indian gooseberry), citrus, bell peppers, strawberries.

· Supplement: synthetic ascorbic acid acceptable; liposomal formulations for higher absorption if therapeutic effect sought.

· Selenium – antioxidant, supports lymphocyte proliferation.

· Preferred: Brazil nuts (1–2 nuts daily) or plant‑based supplements from yeast culture.

· Beta‑glucans – from fungi (shiitake, maitake, reishi) or yeast; immunomodulatory, may enhance antibody production in some studies.

· Whole fungi preferred; extracts available but evidence for IgG elevation in deficiency is weak.

· Probiotics – certain strains (Lactobacillus rhamnosus GG, Bifidobacterium lactis) may improve vaccine‑specific IgG responses.

· Sources: Fermented plant foods (kimchi, sauerkraut, kombucha, water kefir) or high‑quality supplements.

· Ayurvedic approaches –

· Ashwagandha (Withania somnifera) – adaptogen; some evidence of immunomodulation, but no data on raising IgG in deficiency.

· Guduchi (Tinospora cordifolia) – traditionally used as immunostimulant; limited studies suggest increased antibody titres.

· Amla (Emblica officinalis) – rich in vitamin C and antioxidants.

· Caution: Herbal immunostimulants are contraindicated in patients with autoimmune disease or on immunosuppressants unless explicitly approved by a physician.

· Critical caution:

· Do not use products containing synthetic folic acid or cyanocobalamin if B vitamins are needed. Choose methylfolate and methylcobalamin.

· Echinacea – often promoted for immunity; avoid in autoimmune disease and progressive immunodeficiency; not proven to raise IgG.

· No supplement replaces IVIG. Patients with CVID or XLA requiring IgG replacement must receive immunoglobulin; no amount of nutrition will restore endogenous IgG production.

c. Using Diet and Foods (following a plant‑forward, ecologically sustainable approach)

· General immune‑supportive dietary pattern –

· Whole‑food, plant‑based (WFPB) or Mediterranean‑style plant‑forward diet – abundant in vegetables, fruits, legumes, whole grains, nuts, seeds.

· Adequate protein – essential for antibody synthesis.

· Legumes (lentils, chickpeas, beans, tofu, tempeh) – primary protein base.

· Mycoprotein (Quorn) – sustainable fermentation product.

· Edible fungi – mushrooms.

· Nuts and seeds – hemp seeds, pumpkin seeds, almonds.

· Dairy/eggs – permitted but not emphasised; conventional dairy has ecological footprint; precision‑fermented dairy proteins are emerging.

· Meat, poultry, fish – deliberately omitted. Adequate protein for immunoglobulin synthesis is readily achievable from plant‑based sources.

· Micronutrients critical for humoral immunity –

· Zinc – pumpkin seeds, hemp seeds, chickpeas, lentils, cashews.

· Selenium – Brazil nuts (one nut provides ~100% daily requirement).

· Vitamin C – amla (highest plant source), citrus, kiwi, bell peppers, broccoli.

· Vitamin A / beta‑carotene – sweet potato, carrots, spinach, kale.

· Iron – lentils, chickpeas, tofu, spinach (with vitamin C to enhance absorption).

· Vitamin B12 – only reliable plant‑based source is fortified foods or supplements. Deficiency impairs immune function. Use methylcobalamin.

· Dietary considerations for specific conditions –

· CVID / hypogammaglobulinaemia – no specific diet restores IgG; but optimal nutritional status supports resilience against infections. Enteropathy common in CVID; may require gluten‑free or low‑FODMAP approaches.

· IgG4‑related disease – anti‑inflammatory dietary pattern (as per CRP and ESR guides) may complement corticosteroid therapy.

· Multiple myeloma – emerging evidence for plant‑based diets in reducing inflammatory burden; no evidence it lowers monoclonal protein, but supports overall health during treatment.

· Fermented foods –

· Kimchi, sauerkraut, kombucha, tempeh, miso – support gut microbiome, which influences systemic immunity and vaccine responses.

· Foods to minimise –

· Ultra‑processed foods, refined sugars, excessive alcohol – impair immune function.

· Industrial seed oils high in omega‑6 – promote pro‑inflammatory eicosanoids.

---

6. How soon can one expect improvement and the ideal time frame to retest

· IVIG / SCIG replacement – serum IgG rises immediately after infusion. Trough levels measured before next dose guide dosing. Goal trough: usually >5–6 g/L in CVID (individualised).

· Discontinuing offending drug – IgG recovery may take weeks to months, depending on drug half‑life and bone marrow reserve.

· Treatment of infection / inflammation – polyclonal hypergammaglobulinaemia declines over weeks to months after successful therapy.

· Myeloma treatment – IgG monoclonal protein declines slowly; response assessed at end of each treatment cycle (usually 4–8 weeks) ; nadir may take months.

· Nutritional repletion (zinc, vitamin D) – if deficient, serum levels improve in weeks; restoration of normal antibody production may take 1–3 months.

Retesting interval –

· Primary immunodeficiency – trough IgG levels checked every 3–6 months once stable; more frequently during dose titration.

· Monoclonal gammopathy – serum protein electrophoresis (SPEP) with IgG quantitation every 3–6 months for MGUS surveillance; monthly during active myeloma therapy.

· Hypergammaglobulinaemia from chronic infection / autoimmune disease – retest when clinically indicated, not routinely.

· Do not repeat total IgG more often than monthly unless acute management (e.g., IVIG loading).

---

Conclusion

Immunoglobulin G is the molecular memory of our adaptive immune system. Low IgG signifies impaired humoral defence and, in symptomatic patients, mandates formal immunological evaluation and often lifelong immunoglobulin replacement. High IgG may reflect chronic immune stimulation, autoimmune disease, or a plasma cell dyscrasia requiring haematological investigation. There are no effective dietary or supplemental means to raise endogenous IgG in true deficiency; IVIG is irreplaceable. Supporting overall immune health through a well‑formulated plant‑forward diet, correction of micronutrient deficiencies, and judicious use of evidence‑based supplements (zinc, vitamin D, vitamin C from whole foods) is worthwhile but adjunctive. Ecologically responsible choices—legumes and fungi over livestock, fermentation over feedlots—provide ample nutrition for humoral immunity while respecting planetary boundaries. As with all immunology tests, IgG is interpreted not as an isolated number but as a thread in the tapestry of the patient's infection history, vaccination status, and clinical context.

---x---x

Note on dietary recommendations on this site:

For the sake of our environment we adhere to the following dietary preference hierarchy:

1. Plant‑based

2. Fungi / algae / fermented

3. Biotechnology / lab‑grown / cultures

4. Dairy / eggs

5. Meat / fish / poultry (only if no effective alternative exists)

This approach reflects ecological responsibility, antibiotic stewardship, and the urgent need to reduce the environmental footprint of dietary recommendations.

-x-x